Drug Database · Clinicians

Ceftazidime

Brands (79) Hacef, Fortum, Ceftibac…Show all

Antibacterial (cephalosporin); Antibacterial (third-generation cephalosporin); and others PH FDA category

CrCl ≤50: reduce; 1 g after each HDRx · Prescription drug109 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 40d48c5d-650e-461b-a67b-7e65772d1b92, version date May 4, 2026 (TAZICEF · Hospira, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Tazicef (ceftazidime for injection) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Tazicef (ceftazidime for injection) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). 2.

Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. 4.

Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and S taphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6.

Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp.

(many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis.

Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. Tazicef may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient.

When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime) and other antibacterial drugs, Tazicef (ceftazidime) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Hypersensitivity to ceftazidime or other cephalosporins
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS Tazicef is contraindicated in patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibacterial drugs.

Dosing: Adult

  • Usual adult dose: 1 g IV or IM every 8 to 12 hours
  • Uncomplicated urinary tract infection: 250 mg every 12 hours
  • Complicated urinary tract infection: 500 mg every 8 to 12 hours
  • Bone and joint infections: 2 g IV every 12 hours
  • Uncomplicated pneumonia; mild skin infections: 500 mg to 1 g every 8 hours
  • Serious gynecologic or intra-abdominal infection; meningitis; life-threatening infection: 2 g IV every 8 hours
  • CrCl 50 mL/min or less: 1 g load, then 31–50: 1 g q12h; 16–30: 1 g q24h; 6–15: 500 mg q24h; <5: 500 mg q48h
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Dosage The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient. The guidelines for dosage of Tazicef (ceftazidime for injection, USP) are listed in Table 3.

The following dosage schedule is recommended. Table 3. Recommended Dosage Schedule Dose Frequency Adult Usual recommended dosage 1 gram intravenous or intramuscular every 8 to 12 hours Uncomplicated urinary tract infection 250 mg intravenous or intramuscular every 12 hours Bone and joint infections 2 grams intravenous every 12 hours Complicated urinary tract infections 500 mg intravenous or intramuscular every 8 to 12 hours Uncomplicated pneumonia; mild skin and skin-structure infections 500 mg to 1 gram intravenous or intramuscular every 8 hours Serious gynecological and intra-abdominal infections 2 grams intravenous every 8 hours Meningitis 2 grams intravenous every 8 hours Very severe life-threatening infections, especially in immunocompromised patients 2 grams intravenous every 8 hours Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with chronic respiratory disease and cystic fibrosis. 30 to 50 mg/kg intravenous to a maximum of 6 grams per day every 8 hours Neonates (0 – 4 weeks) 30 mg/kg intravenous every 12 hours Infants and children (1 month – 12 years) 30 to 50 mg/kg intravenous to a maximum of 6 grams per day The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis. every 8 hours Impaired Hepatic Function No adjustment in dosage is required for patients with hepatic dysfunction.

Impaired Renal Function Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given.

An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. Table 4. Recommended Maintenance Dosages of Tazicef (Ceftazidime for Injection, USP) in Renal Insufficiency NOTE: if the dose recommended in Table 3 above is lower than that recommended for patients with renal insufficiency as outlined in Table 4, the lower dose should be used.

Creatinine Clearance (mL/min) Recommended Unit Dose of Tazicef Frequency of Dosing 50 to 31 1 gram every 12 hours 30 to 16 1 gram every 24 hours 15 to 6 500 mg every 24 hours less than 5 500 mg every 48 hours When only serum creatinine is available, the following formula (Cockcroft's equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Males: Creatinine clearance (mL/min) = Weight (kg) x (140 - age) 72 x serum creatinine (mg/dL) Females: 0.85 x male value In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately.

Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism. In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.

In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period. Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours.

In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid. Note: Generally, Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required. Administration Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.

Intra-arterial administration should be avoided (see PRECAUTIONS). Intramuscular Administration For IM administration, Tazicef should be constituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5. Intravenous Administration The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.

For direct intermittent IV administration, constitute Tazicef as directed in Table 5 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).

For IV infusion, constitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section. Intermittent IV infusion with a Y-type administration set can be accomplished with compatible solutions.

However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution. Freezing solutions of ceftazidime for injection is not recommended. Table 5. Preparation of Solutions of Tazicef Size Amount of Diluent to be Added (mL) Approximate Available Volume (mL) Approximate Ceftazidime Concentration (mg/mL) Intramuscular 1 gram vial 3 3.6 280 Intravenous 1 gram vial 10 10.6 95 2 gram vial 10 11.2 180 All vials of Tazicef as supplied are under reduced pressure.

When Tazicef is dissolved, carbon dioxide is released and a positive pressure develops. For ease of use please follow the recommended techniques of constitution described on the detachable Instructions for Constitution section of this insert. Solutions of Tazicef, like those of most beta-lactam antibacterial drugs, should not be added to solutions of aminoglycoside antibacterial drugs because of potential interaction.

However, if concurrent therapy with Tazicef and an aminoglycoside is indicated, each of these antibacterial drugs can be administered separately to the same patient.

Dosing: Altered kidney function

Ceftazidime is removed almost entirely by glomerular filtration (80% to 90% unchanged in urine). The US label gives a 1 g loading dose, then reduced maintenance doses when creatinine clearance (CrCl) is 50 mL/min or less, 1 g after each hemodialysis, and 500 mg daily on peritoneal dialysis. High levels in kidney impairment can cause seizures and encephalopathy.

Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); the text refers to GFR <50 mL/min.

Show full dosing details
CrCl ≥60 mL/min
CrCl >50: usual dose (label).
CrCl 30–59 mL/min
CrCl 51–59: usual dose. CrCl 31–50: 1 g every 12 hours (label Table 4). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
CrCl 15–29 mL/min
CrCl 16–30: 1 g every 24 hours; CrCl 15: 500 mg every 24 hours (label Table 4). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
CrCl <15 mL/min (not on dialysis)
CrCl 6–15: 500 mg every 24 hours; below 5: 500 mg every 48 hours (label Table 4; 5 itself not specified). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
Hemodialysis (intermittent)
Loading dose 1 g, then 1 g after each hemodialysis period (label). Literature option (not label): thrice-weekly after each session, 1 g, 1 g and 2 g for organisms with MIC of 8 µg/mL or less, or 2 g, 2 g and 3 g for Pseudomonas aeruginosa (Tsai 2025). These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
Peritoneal dialysis
Label: intraperitoneal dialysis or CAPD, loading dose 1 g, then 500 mg every 24 hours; ceftazidime can also be added to dialysis fluid at 250 mg per 2 L (label). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 1,000 to 1,500 mg daily (long dwell) or 20 mg/kg daily (short dwell); continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
CRRT
Not in label; the cited CRRT review (Li 2020) lists only ceftazidime-avibactam, not ceftazidime alone. Specialist input.
  • Dialyzable? Yes: hemodialysis or peritoneal dialysis may aid removal (label overdose section). Less than 10% protein bound.
  • Monitoring CrCl for dose; seizures, nonconvulsive status epilepticus, encephalopathy, asterixis and myoclonia with high levels in kidney impairment (label); kidney function with aminoglycosides or loop diuretics.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual weight-based dose (label).
eGFR 30–59
Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
eGFR 15–29
Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
eGFR <15 (not on dialysis)
Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
Hemodialysis (intermittent)
No pediatric dialysis dosing in label. Specialist input.
Peritoneal dialysis
No pediatric dialysis dosing in label. Specialist input.
CRRT
No pediatric CRRT data in the cited sources. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

Impaired Renal Function Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given.

An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. Table 4. Recommended Maintenance Dosages of Tazicef (Ceftazidime for Injection, USP) in Renal Insufficiency NOTE: if the dose recommended in Table 3 above is lower than that recommended for patients with renal insufficiency as outlined in Table 4, the lower dose should be used.

Creatinine Clearance (mL/min) Recommended Unit Dose of Tazicef Frequency of Dosing 50 to 31 1 gram every 12 hours 30 to 16 1 gram every 24 hours 15 to 6 500 mg every 24 hours less than 5 500 mg every 48 hours When only serum creatinine is available, the following formula (Cockcroft's equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Males: Creatinine clearance (mL/min) = Weight (kg) x (140 - age) 72 x serum creatinine (mg/dL) Females: 0.85 x male value In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately.

Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism. In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.

In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period. Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours.

In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid. Note: Generally, Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required. Administration Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.

Intra-arterial administration should be avoided (see PRECAUTIONS). Intramuscular Administration For IM administration, Tazicef should be constituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5. Intravenous Administration The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.

For direct intermittent IV administration, constitute Tazicef as directed in Table 5 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).

For IV infusion, constitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV contain

Dosing: Pediatric

Approved ages
Neonates (0 to 4 weeks) and children (label dose table).
Usual dose
Neonates (0 to 4 weeks): 30 mg/kg IV every 12 hours (label). 1 month to 12 years: 30 to 50 mg/kg IV every 8 hours (higher dose for immunocompromised children, cystic fibrosis or meningitis) (label).
Maximum dose
6 g/day (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

Pediatric Use See DOSAGE AND ADMINISTRATION.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Of the 2,221 subjects who received ceftazidime in 11 clinical studies, 824 (37%) were 65 and older while 391 (18%) were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).

Dosage forms

Philippines

  • Powder for injection: 1 g, 2 g, 500 mg
  • Powder for solution for iv infusion: 1 g, 2 g
  • Lyophilized powder for injection: 1 g
  • Sterile powder for injection: 1 g
  • Lyophilized powder for injection n: 1 g
  • Powder for solution for injection: 1 g

Registered products in the Philippines

109 products registered with the Food and Drug Administration (FDA) Philippines list Ceftazidime as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Ceftazidime (as pentahydrate) with sodium carbonate (5 products) · Ceftazidime (as pentahydrate with sodium carbonate) with Sterile Water for Injection (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products109
Philippine FDA-registered products for Ceftazidime
Package insert
AerumCeftazidime
1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with Gray Rubber Stopper and Aluminum Seal and Red Plastic Flip-Off Cap (Box of 10's)
Rx
Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-8558
Nov 10, 2029
AetazCeftazidime (As Pentahydrate)
1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II Clear Glass Vial with Halogenated Butyl Rubber Stopper and Flip-off Seal [Box of 10's]
Rx
Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.China
Dynasty Pharmaceuticals
DR-XY48643
Mar 9, 2028
AetazCeftazidime (as pentahydrate)
1g Powder for Injection (IM/IV)10 mL- capacity USP Type II Clear Glass Vial with Halogenated Butyl Rubber Stopper and Flip-off Seal (Box of 10's)
Rx
Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.China
Dynasty Pharmaceuticals
DRP-13731
Mar 9, 2028
BizazolineCeftazidime
1g Powder for injection (IV)Type II Transparent Glass Vial with bromobutyl stopper and gray aluminum flip-off seal (Box of 1's and 10's)
Rx
Laboratorio Reig Jofre S.A.España
Penta Labs Australia (Philippines)
DRP-7427
Oct 25, 2027
BizazolineCeftazidime
2g Powder for Injection (IV)Type II Transparent Glass Vial with bromobutyl stopper and gray aluminum flip-off seal (Box of 1's and 10's)
Rx
LABORATORIO REIG JOFRE S.AEspaña
PENTA LABS AUSTRALIA (PHILIPPINES)
DRP-7428
Oct 25, 2027
BrizamideCeftazidime (as pentahydrate) with sodium carbonateVariant spelling
1 g Powder for Injection (IM/IV)20 mL-capacity borosilicate glass vial with rubber stopper and alu-plastic caps (Box of 10's)
Rx
Chengdu Brilliant Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-15186
May 22, 2029
CefbexaCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Pharmakon Biotec Inc.Importer: Pranish Inc.
DRP-14987-05
Dec 20, 2028
CefdimeCeftazidime (as Pentahydrate)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's)
Rx
NCPC Hebei Huamin Pharmaceutical Co., Ltd.China
Southmed Pharma CorporationImporter: Aglobal Care, Inc.
DRP-6180-06
Mar 13, 2029
CefdimeCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Southmed Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-8473-03
Jul 15, 2029
CefedixCeftazidime (as pentahydrate)
1g Powder for Injection (IM/IV)20 mL-capacity USP Type III Clear Glass Vial with grey butyl rubber stopper and blue coloured aluminum flip off seal (Box of 1's)
Rx
Scott-Edil Advance Research Laboratories & Education LimitedIndia
Teramedix Pharma Trading Inc.
DR-XY47818
Mar 15, 2027
CeftabrilCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)Clear colorless borosilicate glass vial with butyl rubber stopper and aluminum plastic cap (Box of 10's)
Rx
Chengdu Brilliant Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-18535
Jul 28, 2031
CeftacentCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Central West Medicale Inc.Importer: Greencore Pharma Inc.
DRP-11577-03
Mar 31, 2027
CeftadimeCeftazidime (As Pentahydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Scott-Edil Advance Research Laboratories & Education LimitedIndia
Pharmakon Biotec Inc.
DR-XY48131
Jul 1, 2027
CeftadimeCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1 's)
Rx
Scott-Edil Advance Research Laboratories & Education LimitedIndia
Pharmakon Biotec Inc.
DRP-13426
Jul 1, 2027
CeftaflaxCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Teramedix Pharma Trading Inc.Importer: Pranish Inc.
DRP-14987-02
Dec 20, 2028
CeftakonCeftazidime (as pentahydrate)
1 g Sterile Powder for Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with 20 mm grey butyl rubber stopper and blue flip-off cap with aluminum seal (Box of 1's)
Rx
Sance Laboratories Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-9665
Jul 15, 2031
CEFTAMEDCEFTAZIDIME (AS PENTAHYDRATE)
1 G POWDER FOR INJECTION (IV/IM)USP TYPE I CLEAR GLASS VIAL BOX OF 10'S
Rx
HANKOOK KORUS PHARM. CO., LTD.Republic of Korea
Importer: MG PRIME PHARMACEUTICAL, INC.
DR-XY43773
Oct 2, 2029
CeftamedzCeftazidime (as pentahydrate)
1 g Sterile Powder for InjectionType I Transparent Glass vial with rubber stopper and red flip-off seal
Rx
Shandong Xier Kangtai Pharmaceuticals Co., Ltd.China
JF Draf Pharmaceuticals Corporation
DRP-3724
Oct 8, 2028
CeftanovaCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)10 mL-capacity USP type III clear glass vial with rubber stopper and aluminum orange flip-off seal (Box of 1's)
Rx
Finebiotics Pharma Ltd.India
Medinova Pharmaceutical Inc.
DRP-16459
Mar 18, 2030
CeftazicareCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Teramedix Pharma Trading Inc.Importer: Pranish Inc.
DRP-14987-01
Dec 20, 2028
CEFTAZIDENCeftazidime (as Pentahydrate)
1 g Powder for Injection (IM/IV)20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s) Box of 10's
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina
Cyden Medicale Trading Inc.Importer: AMB HK ENTERPRISES INC.
DRP-8473-02
Jul 15, 2029
CeftazigenCeftazidime
1 g Powder For Injection (Im/Iv)1g USP Type I Colorless Glass Vial with butyl rubber stopper and violet flip-off cap (Box of 10's)
Rx
PHIL INTER PHARMA CO., LTD.Vietnam
Importer: LARGEN MED INC.
DRP-5391
Dec 3, 2028
Ceftazimed-1Ceftazidime (as pentahydrate) with sodium carbonateVariant spelling
1g Lyophilized Powder for Injection (IM/IV) n10 mL-capacity USP Type II Glass vial with rubber stopper and flip- off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-14309
Aug 16, 2028
Ceftazimed-1 PlusCeftazidime (as pentahydrate with sodium carbonate) with Sterile Water for InjectionVariant spelling
1g Lyophilized Powder for Injection (IM/IV)In a box, 10 mL-capacity USP Type II Glass vial with rubber stopper and flip-off cap and Amber Glass Ampoule x 10 mL (diluent)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-14310
Aug 16, 2028
CeftazinCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL USP Type I Clear Glass Vial x with Burgundy Flip-off Seal (Box of 1's)
Rx
United Biotech Pvt. LimitedIndia
Delex Pharma International, Inc.
DRP-10468
Mar 3, 2031
CeftazisaphCeftazidime (as Pentahydrate)
1 g Powder for Injection (IV/IM)Type I Flint Glass Vial with Grey Bromobutyl Rubber Stopper and Alu/PP Flip-Off Seal x 1's (Box of 1's and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10684
Nov 5, 2031
CeftazivitCeftazidime (as pentahydrate)
1g Powder for Injection (I.M. / I.V.)USP Type I Clear and Colorless Glass Vial with Rubber Stopper and Red Flip Off Seal Box of 1's and 10's
Rx
Vitalis S.A.C.I.Colombia
Pan-Ject Pharmaceuticals Corp.Trader: Vitalis S.A.C.I.
DRP-2395
Mar 18, 2029
CeftebasCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)USP type I Glass Vial with 5 mL Sterile Water for Injection (Box of 1's)
Rx
Neutro Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DR-XY38098
Jun 22, 2030
CeftibacCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)USP Type I Vial with 10mL Diluent (Box of 1's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY37334
Jan 12, 2030
CeftibacCeftazidime (as Pentahydrate)
1g Powder for Injection (I.M./I.V.)USP Type II vial Box of 10's
Rx
Singapore Pharmawealth Lifesciences, IncPhilippines
—
DR-XY37504
Feb 17, 2030
CeftibacCeftazidime (as Pentahydrate)
1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co. Ltd. Gen. Pharm FactoryChina
Phil Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16748-01
Jan 18, 2028
CeftibacCeftazidime (as Pentahydrate)
500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co. Ltd. Gen. Pharm FactoryChina
Phil Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16747-01
Jan 7, 2028
CeftibacCeftazidime (as Pentahydrate)
500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial + 5 mL LDPE Vial as Diluent (Box of 1's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY36467
Aug 13, 2029
CeftidinCeftazidime (as pentahydrate)
2 g Powder for Injection (IM/IV)USP Type I Glass Vial x 20 mL (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-6146
May 8, 2030
CefwideCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL USP Type I Flint Glass Vial with grey bromobutyl rubber stopper (Box of 1's)
Rx
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-4916
Nov 13, 2028
Cestazid 1000Ceftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3389
Nov 10, 2031
DemicefCeftazidime (as pentahydrate)
1 g Powder For Injection (IM/IV)20 mL clear colorless borosilicate glass vial with butyl rubber stopper and aluminium plastic cap (Box of 1's and 10's)
Rx
Chengdu Brilliant Pharmaceutical Co., Ltd.China
Philgen Pharmaceuticals Inc.
DRP-13427
Feb 15, 2028
DimzefCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Clear colorless glass vial with rubber stopper and violet colored flip-off seal (Box of 10’s)
Rx
Chong Kun Dang Pharmaceutical Corp.Republic of Korea
Unimex, Inc.
DRP-2831
Mar 19, 2028
ElbazidCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc.
DRP-11577-02
Mar 31, 2027
Eozidime-1000Ceftazidime
1 g Powder for Solution for Injection (I.M./I.V.)20 mL Clear Glass Vial (Box of 1's)
Rx
Zee Laboratories LimitedHimachal Pradesh India
Eon Pharmatek Inc.
DR-XY48221
Jul 25, 2032
ErazideCeftazidime
1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL Box of 1's
Rx
Brawn Laboratories Ltd.India
Pharmalife DistributionImporter: Ambica International Corporation
DRP-6053
May 13, 2030
FlazidemCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Clear glass vial with rubber stopper and white flip-off seal (Box of 1’s)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-950
Oct 23, 2027
FortumCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
ACS Dobfar S.p.A.Italy
Sandoz Philippines Corporation
DR-XY16156
Jun 4, 2029
FortumCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s)
Rx
ACS Dobfar S.p.A.Italy
Sandoz Philippines Corporation
DRP-11863
Jun 4, 2029
FortumCeftazidime (as pentahydrate)
2 g Powder for Solution for IV InfusionType III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
ACS Dobfar S.P.A.Italy
Sandoz Philippines Corporation.
DR-XY3848
Jun 4, 2029
FortumCeftazidime (as pentahydrate)
2 g Powder for Solution for IV InfusionType III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s)
Rx
ACS Dobfar S.P.A.Italy
Sandoz Philippines Corporation.
DRP-11853
Jun 4, 2029
FortumCeftazidime (as pentahydrate)
500 mg Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
ACS Dobfar S.p.A.Italy
Sandoz Philippines Corporation.
DR-XY16118
Jun 4, 2029
FortumCeftazidime (as pentahydrate)
500 mg Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s)
Rx
ACS Dobfar S.p.A.Italy
Sandoz Philippines Corporation
DRP-11862
Jun 4, 2029
FortzidCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’S)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises Inc.
DRP-8473
Jul 15, 2029
ForzidCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)1 Vial (1 g) in a Box
Rx
PT. Dankos FarmaIndonesia
Lakeside Pharmaceuticals Phil., Inc.
DR-XY26592
Sep 26, 2027
FotaranCeftazidime (as pentahydrate)
1 g Powder for Injection (IV/IM)20 mL USP Type III flint moulded vial with 20 mm grey bromobutyl rubber plug (Box of l's)
Rx
VHB Medi Sciences LimitedIndia
Brady Pharma Inc.
DR-XY47863
Mar 31, 2027
FROXETACeftazidime (as Pentahydrate)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
LABMATE PHARMA INC.Importer: AGLOBAL CARE, INC.
DRP-6180-01
Mar 13, 2029
GozidimeCeftazidime
1g Powder For Injection (IM/IV)15 mL USP Type III Flint Glass Vial (Box of 1's)
Rx
Yeluri Formulations Pvt. Ltd.India
Generic Option Pharma Corp.
DRP-12560
Sep 2, 2027
HacefCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M/I.V)USP Type I Vial x 1’s (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. Factory, EU Formulation WorkshopChina
Endure Medical, Inc.
DRP-16749
Apr 18, 2031
HacefCeftazidime (as Pentahydrate)
1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY34160
Jan 18, 2028
HacefCeftazidime (as Pentahydrate)
1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DRP-16748
Jan 18, 2028
HacefCeftazidime (as Pentahydrate)
2 g Powder for Injection (IM/IV)USP Type I Vial + 2 Ampoules x 5 mL Diluent
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm FactoryChina
Endure Medical, Inc.
DR-XY34508
Apr 21, 2030
HacefCeftazidime (as Pentahydrate)
500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY34129
Jan 7, 2028
HacefCeftazidime (as Pentahydrate)
500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DRP-16747
Jan 7, 2028
HacefCeftazidime (as pentahydrate)
500 mg Powder for Injection (IM/IV)USP Type I Vial x 1's (Box of 10’s)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DRP-17405
Apr 18, 2031
HalcefCeftazidime (As Pentahydrate)
1 g Powder For Injection (IM/IV)USP Type I transparent glass vial with 20 mm grey buty rubber stopper and aluminum flip off seal with coloured polypropylene plastic seal (Box of 1's)
Rx
Medisure Laboratories Pakistan Pvt LtdPakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-11739
Apr 22, 2027
J-TazidimCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M / I.V)USP Type I Borosilicate Glass Vial (Box of 10's)
Rx
Dongkwang Pharm. Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: JLT PHARMA INC.
DRP-7950
Jun 11, 2029
KeftamCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal / (Box of 1's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
THE CATHAY DRUG CO., INC.Importer: AGLOBAL CARE, INC
DRP-6180-03
Mar 13, 2029
KERAZINECeftazidime (as Pentahydrate)
1 g Powder for Injection20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s) Box of 10's
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina
PhilRx Pharma IncImporter: AMB HK ENTERPRISES INC.
DRP-8473-01
Jul 16, 2029
LuozidimeCeftazidime (as pentahydrate) with sodium carbonateVariant spelling
1 g Powder for Solution for IV Infusion10 mL-capacity soda-lime glass vial with rubber stopper and aluminum plastic caps (Box of 1's)
Rx
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China
Luoxin Pharmaceuticals (PH) Corp.
DRP-15159
May 16, 2029
MedtazimeCeftazidime (As Sodium)
1 g Powder For Injection (Im/Iv)20 mL Type I Glass Vial with Gray Bromobutyl Rubber Stopper and Sealed with Aluminum Plastic Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Ananta Medicare LimitedIndia
Medinova Pharmaceutical, Inc.
DRP-14218
Jul 28, 2028
NoneCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
RiteMED Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3389-02
Sep 11, 2037
NoneCeftazidime (as Pentahydrate)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Co., Ltd.China
Connectwell Pharma Inc.Importer: AGlobal Care, Inc.
DRP-6180-05
Mar 13, 2029
NoneCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M/I.V)10mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.
DRP-6180-02
Mar 13, 2029
NoneCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)USP Type I glass vial with aluminum red plastic flip-off cap (Box of 10's)
Rx
Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DR-XY40158
Oct 11, 2030
NoneCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-oof seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish Inc.
DRP-14987
Dec 20, 2028
NoneCeftazidime (as pentahydrate)
1 g Powder for Injection (IV/IM)Clear Glass Vial with Red Flip-off Cap + 10 mL Clear Glass Ampoule Diluent (Water for Injection) in a Box (Box of 1's)
Rx
Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan
Nueva Sunshine Phils., Inc.Importer: Sahar International Trading Inc.
DRP-13689-03
Mar 5, 2029
NovazidimeCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip-off seal (Box of l's)
Rx
Yeluri Formulations Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-11601
Mar 31, 2027
OnetazidCeftazidime
1 g Powder for Injection (IM/IV)USP Type I Clear and Colorless Vial x 10 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
One Pharma Marketing Inc.Importer: Ambica International Corporation
DRP-6053-02
May 13, 2030
QualicefCeftazidime (as pentahydarte)
1 g Powder for Injection10 mL USP Type I clear and colorless glass vial (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Qualifirst Health Inc.
DR-XY41800
Mar 13, 2028
RetazidimeCeftazidime (as pentahydrate) with sodium carbonateVariant spelling
1 g Lyophilized Powder for Injection (IM/IV)10 mL-capacity USP Type II Glass vial with rubber stopper and flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Reta DrugImporter: Dreamax Incorporated
DRP-14309-01
Aug 16, 2028
RobedimCeftazidime
1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL Box of 1's
Rx
Brawn Laboratories Ltd.India
RSG Pharma TradingImporter: Ambica International Corporation
DRP-6053-01
May 13, 2030
SaltazCeftazidime (as pentahydrate) with sodium carbonateVariant spelling
1 gram Powder for Injection (IM/IV)Glass vial with rubber stopper and alu-plastic caps (Box of 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
Golden Life Pharmaceutical Product DistributionTrader: Salubris Pharmaceuticals Limited
DRP-16515
Apr 8, 2030
Sanzidime-1000Ceftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)Type I Glass Vial x 20 mL (Box of 1's)
Rx
Sance Laboratories Pvt. Ltd.India
AMB HK Enteprises Inc.
DRP-5571
Nov 7, 2028
SeftaCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial + 10 mL Ampoule Water for Injection (Box of 1's)
Rx
Geofman PharmaceuticalsPakistan
Sahar International Trading, Inc.
DR-XY38717
Nov 3, 2030
SherzidCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Type III Clear and Colorless Glass Vial (Box of 1’s)
Rx
Yeluri Formulations Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-4783
Oct 8, 2028
SITI-ZIDECeftazidime (as pentahydrate)
1 g Powder for Injection (IV/IM)Clear Glass Vial with Red Flip-off Cap + 10 mL Clear Glass Ampoule Diluent (Water for Injection) in a Box
Rx
Bosch Pharmaceuticals Pvt. Ltd.Pakistan
Sahar International Trading, Inc.
DRP-13689
Mar 5, 2029
SurtazidCeftazidime (as Pentahydrate)
1g Powder for Injection (IV/IM)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip Off Seal (Box of 10's)
Rx
Yeluri Formulations Pvt. Ltd.India
Pharma-Surrey International, Inc.
DRP-10330
Sep 10, 2031
TarzidimeCeftazidime (as pentahydrate with sodium carbonate)
1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II clear glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., LtdChina
Philgen Pharmaceuticals Inc.
DRP-16422
Mar 5, 2030
TazicefCeftazidime(as pentahydrate) (with sodium carbonate)
1g Powder for Injection(IM/IV)Clear Glass Vial with Rubber Stopper & Blue Flip-off Seal x 1 g (Box of 10’s)
Rx
Shin Poong Pharmaceutical Co., Ltd.Republic of Korea
Phil. Shinpoong Pharma, Inc.
DRP-289
Jul 27, 2031
TazidemCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)BP Type I Colorless Glass Vial x 1's Box of 1's
Rx
Samchundang Pharm. Co., Ltd.Republic of Korea
PharmAsia-Cuvest, Incorporated
DR-XY41116
Aug 3, 2027
TazidemCeftazidime
1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL (Box of 1’s)
Rx
Brawn Laboratories Ltd.India
Pharmasia-Cuvest IncorporatedImporter: Ambica International Corporation
DRP-6053-03
May 13, 2030
TazidexCeftazidime (as pentahydrate)
1 g Powder For Injection (IM/IV)10 mL Capacity Type I Flint Vial Sealed With Grey Butyl Rubber Stopper And Aluminum Seal with Flip-off Plastic Cap x 1's (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Philrx Pharma Inc.
DRP-18648
Aug 12, 2031
TazidimeCeftazidime (as pentahydrate)
1 g Powder for Injection (I.V/I.M.)Clear glass vial with red Flip-off cap + 10 mL Clear glass ampoule Diluent (Water for Injection) in a box
Rx
Bosch Pharmaceuticals, Pvt. Ltd.Pakistan
Jalmedbase Pharma Corp.Importer: Sahar International Trading Inc.
DRP-13689-02
Mar 5, 2029
TazifCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal/ (Box of 1's)
Rx
Vellinton HealthcareIndia
Teramedix Pharma Trading Inc.Importer: Pranish Inc.
DRP-14987-03
Dec 20, 2028
TazilukeCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
Alpace Pharmaceutical DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3389-01
Sep 22, 2037
TazimCeftazidime (as Pentahydrate)
1 g Powder for Injection (I.M./I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Sandoz GmbHAustria
Importer: Sandoz Philippines Corporation
DRP-4445
Jul 26, 2027
TaziseaCeftazidime (as pentahydrate)
1g Powder For Injection (IV/IM)15 mL-capacity USP type III Clear Glass Vial with grey butyl rubber stopper and yellow color aluminum propylene flip-off seal (Box of l's)
Rx
Yeluri Formulations Pvt. Ltd.India
Seapharma International Inc.
DRP-11070
Jan 21, 2027
TazisheenCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1 's)
Rx
Scott-Edil Advance Research Laboratories & Education LimitedIndia
Farmacia SheenaImporter: Pharmakon Biotec, Inc.
DRP-13426-01
Jul 1, 2027
TazisheenCeftazidime
1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Farmacia SheenaImporter: Pranish Inc.
DRP-14987-04
Dec 20, 2028
TazivexCeftazidime
1 g Powder for Injection (IM/IV)Individually boxed Type II glass vial with brownish-yellow flip-off seal (Box of 10's)
Rx
Shandong Xier Kangtai Pharmaceutical Co., Ltd.China
Sannovex Pharmaceutical Distributor
DRP-2490
Aug 3, 2028
TriceftazCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc.
DRP-11577-01
Mar 31, 2027
VidimeCeftazidime (as Pentahydrate)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Co., Ltd.China
Vintel Med EnterprisesImporter: Aglobal Care, Inc.
DRP-6180-04
Mar 13, 2029
ZatfecCeftazidime (as pentahydrate)
500 mg Powder for Injection (IM/IV)USP Type II clear and colorless glass vial sealed with bromobutyl rubber stopper and blue flip-off seal + clear and colorless glass ampoule (Sterile Water for Injection as solvent) [Box of 1's]
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Ambica International Corporation
DRP-7398
Oct 9, 2027
ZefadimeCeftazidime (as pentahydrate)
1g Powder for Injection (I.M./I.V)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip-off seal (Box of 1's)
Rx
Yeluri Formulation Pvt. Ltd.India
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical, Inc.
DRP-11601-01
Mar 31, 2027
ZeftacareCeftazidime (as Pentahydrate)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
AGLOBAL CARE, INC.
DRP-6180
Mar 13, 2029
ZeftasaveCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)USP Type I transparent glass vial with 20 mm grey butyl rubber stopper and aluminum flip off seal with coloured polypropylene plastic seal (Box of 10's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Savelink Pharma And Trading CoImporter: Accesspoint International Trading Inc.
DRP-11739-01
Apr 22, 2027
ZeptrigenCeftazidime (as pentahydrate)
1 g Powder for Injection (IM/IV)Type I Glass Vial Sealed with Grey Rubber Stopper and Green Aluminum Flip-Off Seal Box of 1's and Box of 10's (with plastic tray); Type I Glass Vial Sealed with Grey Rubber Stopper and Alucap Metallic Green Box of 1's and Box of 10's (with plastic tray)
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, INC.
DR-XY27651
Oct 24, 2027
ZeptrigenCeftazidime (as pentahydrate)
500 mg Powder for Injection (IM/IV)Type I glass vial sealed with grey rubber stopper and green aluminum flip-off seal; grey rubber stopper and alucap metallic green seal (Box of 1's, Box of 10's (with plastic tray))
Rx
PT Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DR-XY27652
Oct 24, 2027
ZidicefCeftazidime (as Pentahydrate)
1 g Powder for Injection (IM/IV)10 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Pink Flip-off Seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Sanimed Pharmaceuticals Inc.
DRP-6843
Sep 23, 2031
ZidimeCeftazidime (as pentahydrate)
1 g Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1’s)
Rx
Makcur Laboratories LimitedIndia
Penta Labs Australia (Philippines)Trader: U Square Lifesciences Pvt. Ltd.
DRP-12364
Jul 25, 2027
ZidmaxCeftazidime (As Pentahydrate)
1g Powder For Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Greencore Pharma Inc.
DRP-11577
Mar 31, 2027
(no brand name)Ceftazidime
1 g Powder for Injection (IM/IV)20 mL-capacity clear glass vial with rubber stopper amd magenta aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish Inc.
DR-XY48948
Dec 20, 2028
(no brand name)Ceftazidime (as pentahydrate with sodium carbonate)
1 g Powder for Injection (IM/IV)10 mL-capacity USP type II clear glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Khriz Pharma Trading Inc.
DR-XY49171
Aug 15, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS BEFORE THERAPY WITH TAZICEF IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.

IF AN ALLERGIC REACTION TO TAZICEF OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ceftazidime, and may range in severity from mild diarrhea to fatal colitis.

Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.

CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.

Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see PRECAUTIONS).

Drug interactions

Drug or classSeverityEffectWhat to do
Aminoglycosides; potent loop diuretics (furosemide)Adjust or monitorNephrotoxicity reported with cephalosporins given with these drugs (label).Monitor kidney function.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.

Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials. Chloramphenicol has been shown to be antagonistic to beta-lactam antibacterial drugs, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.

Adverse reactions

Common

  • Local reactions after IV injection (phlebitis)
  • Allergic reactions (rash, pruritus)
  • Gastrointestinal effects (diarrhea, nausea)

Serious

  • Anaphylaxis (cross-reactivity with penicillins up to 10%)
  • Seizures, nonconvulsive status epilepticus, encephalopathy in kidney impairment
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Ceftazidime is generally well tolerated. The incidence of adverse reactions associated with the administration of ceftazidime was low in clinical trials. The most common were local reactions following IV injection and allergic and gastrointestinal reactions. Other adverse reactions were encountered infrequently.

No disulfiram-like reactions were reported. The following adverse effects from clinical trials were considered to be either related to ceftazidime therapy or were of uncertain etiology: Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients). Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever.

Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been reported with cephalosporin antibacterial drugs, including ceftazidime. Angioedema and anaphylaxis (bronchospasm and/or hypotension) have been reported very rarely.

Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78), nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS). Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and paresthesia.

Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime (see PRECAUTIONS: General). Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and vaginitis.

Hematologic Rare cases of hemolytic anemia have been reported. Laboratory Test Changes noted during clinical trials with Tazicef (ceftazidime for injection, USP) were transient and included: eosinophilia (1 in 13), positive Coombs test without hemolysis (1 in 23), thrombocytosis (1 in 45), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase (AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19), and alkaline phosphatase (1 in 23).

As with some other cephalosporins, transient elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and lymphocytosis were seen very rarely. Postmarketing Experience with Tazicef (ceftazidime for injection, USP) Products In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with Tazicef and were reported spontaneously.

For some of these events, data are insufficient to allow an estimate of incidence or to establish causation. General Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria; pain at injection site. Hepatobiliary Tract Hyperbilirubinemia, jaundice. Renal and Genitourinary Renal impairment.

Cephalosporin-Class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with ceftazidime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs: Adverse Reactions Colitis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage. Altered Laboratory Tests Prolonged prothrombin time, false-positive test for urinary glucose, pancytopenia.

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-438-1985, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Monitoring parameters

  • CrCl for dose; seizures, nonconvulsive status epilepticus, encephalopathy, asterixis and myoclonia with high levels in kidney impairment (label); kidney function with aminoglycosides or loop diuretics. Kidney
  • CrCl for dose
  • Neurologic status in kidney impairment
  • Kidney function with aminoglycosides or loop diuretics
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Tazicef. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Ceftazidime is excreted in human milk in low concentrations. Caution should be exercised when Tazicef is administered to a nursing woman.

Pharmacokinetics

Key PK parameters

Half-lifeAbout 1.9 hours (IV)
Half-life in kidney failure (ESKD) kidneySignificantly prolonged in kidney impairment (label; no value given)
Protein bindingLess than 10%
Metabolism (CYP, transporters)Not metabolized
Active metabolitesNone
Renal excretion kidney80% to 90% unchanged in urine over 24 hours (glomerular filtration)
Dialyzability kidneyYes (hemodialysis and peritoneal dialysis; label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

The half-life following IV administration was approximately 1.9 hours.

The half-life of ceftazidime in these volunteers was approximately 2 hours.

Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period.

An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later.

The mean renal clearance of ceftazidime was approximately 100 mL/min.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY After IV administration of 500-mg and 1-g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg, 1-g, and 2-g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved.

The average serum concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers over an 8-hour interval are given in Table 1 Table 1. Average Serum Concentrations of Ceftazidime Ceftazidime IV Dose Serum Concentrations (mcg/mL) 0.5 hr 1 hr 2 hr 4 hr 8 hr 500 mg 42 25 12 6 2 1 g 60 39 23 11 3 2 g 129 75 42 13 5 The absorption and elimination of ceftazidime were directly proportional to the size of the dose.

The half-life following IV administration was approximately 1.9 hours. Less than 10% of ceftazidime was protein bound. The degree of protein binding was independent of concentration. There was no evidence of accumulation of ceftazidime in the serum in individuals with normal renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.

Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL, respectively, at approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and 8 hours after the IM administration of 500-mg and 1-g doses, respectively.

The half-life of ceftazidime in these volunteers was approximately 2 hours. The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage adjustment from the normal recommended dosage is not required for patients with hepatic dysfunction, provided renal function is not impaired.

Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later.

The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine. The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime.

This suggested that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function. Consequently, dosage adjustments in such patients as described in the DOSAGE AND ADMINISTRATION section are suggested.

Therapeutic concentrations of ceftazidime are achieved in the following body tissues and fluids. Table 2. Ceftazidime Concentrations in Body Tissues and Fluids Tissue or Fluid Dose/Route No. of Patients Time of Sample Post Dose Average Tissue or Fluid Level (mcg/mL or mcg/g) Urine 500 mg IM 6 0 to 2 hr 2,100 2 g IV 6 0 to 2 hr 12,000 Bile 2 g IV 3 90 min 36.4 Synovial fluid 2 g IV 13 2 hr 25.6 Peritoneal fluid 2 g IV 8 2 hr 48.6 Sputum 1 g IV 8 1 hr 9 Cerebrospinal fluid 2 g q8hr IV 5 120 min 9.8 (inflamed meninges) 2 g q8hr IV 6 180 min 9.4 Aqueous humor 2 g IV 13 1 to 3 hr 11 Blister fluid 1 g IV 7 2 to 3 hr 19.7 Lymphatic fluid 1 g IV 7 2 to 3 hr 23.4 Bone 2 g IV 8 0.67 hr 31.1 Heart muscle 2 g IV 35 30 to 280 min 12.7 Skin 2 g IV 22 30 to 180 min 6.6 Skeletal muscle 2 g IV 35 30 to 280 min 9.4 Myometrium 2 g IV 31 1 to 2 hr 18.7 Microbiology Mechanism of Action Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.

Ceftazidime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Mechanism of Resistance Resistance to ceftazidime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.

Interaction with Other Antimicrobials In an in vitro study, antagonistic effects have been observed with the combination of chloramphenicol and ceftazidime. Ceftazidime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-negative bacteria

  • Citrobacter species
  • Enterobacter species
  • Escherichia coli
  • Klebsiella species
  • Haemophilus influenzae
  • Neisseria meningitidis
  • Proteus mirabilis
  • Proteus vulgaris
  • Pseudomonas aeruginosa
  • Serratia species Gram-positive bacteria
  • Staphylococcus aureus
  • Streptococcus pneumoniae
  • Streptococcus pyogenes
  • Streptococcus agalactiae Anaerobic bacteria
  • Bacteroides species (Note: many isolates of Bacteroides species are resistant) The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for ceftazidime. However, the efficacy of ceftazidime in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials. Gram-negative bacteria
  • Acinetobacter species
  • Citrobacter diversus
  • Citrobacter freundii
  • Providencia species (including Providencia rettgeri)
  • Salmonella species
  • Shigella species
  • Haemophilus parainfluenzae
  • Morganella morganii
  • Neisseria gonorrhoeae
  • Yersinia enterocolitica Gram-positive bacteria
  • Staphylococcus epidermidis Anaerobic bacteria
  • Clostridium species (Not including Clostridium difficile)
  • Peptostreptococcus species Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ceftazidime 1 g Vial₱19.00–₱68.00Reference ₱34.00per vialDPRI procurement range
Ceftazidime 500 mg Vial₱58.87–₱297.88Reference ₱288.44per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ceftaxidime (Ceftazidime)
PNF listingInj.: 250 mg, 500 mg and 1 g vial (IM, IV) (as pentahydrate)
PNF listingInj.: 2 g vial (IV infusion) (as pentahydrate)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. TAZICEF · Hospira, Inc. [US FDA-approved label, version 16, May 4, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Hospira, Inc. (2026). TAZICEF (ceftazidime for injection, USP) [Prescribing information; US FDA-approved label, ANDA062662, set ID 40d48c5d-650e-461b-a67b-7e65772d1b92, version effective May 4, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
  6. Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
  7. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .